Antonio Sifuentes ÁA, Talamás MJ, Reyes VF, Reyes RM

Language: Spanish
References: 9
Page: 22-29
PDF size: 359.85 Kb.

ABSTRACT

Background: Recently osteopontin was associated with breast cancer, but has not studied the risk conferred by polymorphic variants of the gene encoding SPP1.
Objective: To determine the association between breast cancer, polymorphisms T-66G and G-156GG SPP1 gene, haplotypes formed by them, and serum osteopontin in women in northern Mexico.
Method: A case-control study with 150 cases and 225 controls of patients treated at the Cancer Center of Durango State. All participants gave their informed consent. The determination of the polymorphisms was performed by DNA fused high resolution and osteopontin by ELISA. Statistical analysis was performed using Haploview and Episheet.
Results: for G-156GG polymorphism, the model showed allele odds ratio (OR) of 2.25, and the dominant model of 2.74 RM. The value of standardized linkage disequilibrium of 0.15. The GG haplotype -66G/-158 -66T/-158GG and MRI showed 1.84 and 4.70, respectively. The concentration of osteopontin was higher in cases (p ‹0.001). No association of alleles and genotypes with concentration of osteopontin.
Conclusions: These results suggest that allele-156GG SPSS1 increases the risk of cancer. Osteopontin is elevated in patients with breast cancer, but no association with the alleles or genotypes studied. This is the first study in Mexican population of polymorphisms in the promoter region of SPP1 contributes to characterize the genetic structure of our population.

REFERENCES

1. Hidalgo-Miranda A, Jiménez-Sánchez G. Bases genómicas del cáncer de mama: avances hacia la medicina personalizada. Salud Publica Mex 2009;51 Suppl 2:s197-207.

2. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, et al Osteopontin-a molecule for all seasons. Q J Med 2002;95:3-13.

3. Kariuki SN, Moore JG, Kirou KA, Crow MK, et al. Ageand gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus. Genes Immun 2009;10:487-494.

4. Ribner A, Altarescu G, Zimran A, Elstein D. Osteopontin polymorphic susceptibility factor for Parkinson's disease among patients with Gaucher disease. Mov Disord 2011;26:1341-3.

5. Suzuki M, Mose E, Galloy C, Tarin D. Osteopontin gene expression determines spontaneous metastatic performance of orthotopic human breast cancer xenografts. Am J Pathol 2007; 171(2):682-692.

6. Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 2010;103:861-869.

7. Weber GF, Lett GS, Haubein NC. Categorical meta-analysis of Osteopontin as a clinical cancer marker. Oncol Rep 2011;25:433-441.

8. Giacopelli F, Marciano R, Pistorio A, Catarsi P, et al. Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics 2004;20:87-96.

9. D'Alfonso S, Barizzone N, Giordano M, Chiocchetti A, et al. Two single-nucleotide polymorphisms in the 5' and 3' ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum 2005;52:539-547.